Distinct features of IgG2 aquaporin-4 antibody carriers with neuromyelitis optica.
Distinct features of IgG2 aquaporin-4 antibody carriers with neuromyelitis optica.
复制标题
IgG2 水通道蛋白 4 抗体携带者患有视神经脊髓炎的独特特征。
DOI：
10.1111/cen3.12179
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Kira J.
中科院分区：
文献类型：
--
作者：
Isobe N;Yonekawa T;Matsushita T;Kawano Y;Masaki K;Yoshimura S;Murai H;Yamasaki R;Kira J.
目的视神经脊髓炎(Neuromyelitis optica，NMO)是一种特异性检测针对水通道蛋白4(AQP4)的NMO免疫球蛋白G(NMO-Ig G，Ig G)的炎症性疾病。虽然AQP4抗体的主要亚类被报道为IgG1亚类，但其他亚类也被描述为第二常见亚类，包括IgG2 AQP4抗体。方法采用建立的流式细胞仪检测58例符合2006年修订标准的NMO患者血清中AQP4抗体亚类的表达，并根据主要AQP4抗体亚类比较其临床特征。结果50例(86.2%)患者存在IgG1AQP4抗体，其中8例(13.8%)为主要抗体亚类。与IgG1AQP4抗体表达的患者相比，这8例患者的发病年龄更小(P=0.0089)，AQP4抗体滴度更低(P=0.0024)，更符合巴克霍夫标准(P=0.0466)。结论本研究结果提示以IgG2AQP4抗体为主要亚型的患者的特征更类似于多发性硬化症，而与IgG1AQP4抗体的NMO患者有所不同。
ObjectiveNeuromyelitis optica (NMO) is an inflammatory disease in which NMO‐immunoglobulin G (IgG) targeting aquaporin‐4 (AQP4) is specifically detected. Although the main subclass of AQP4 antibody was reported to be in the IgG1 subclass, other subclasses have also been described, including IgG2 AQP4 antibody, as a second common subclass. NMO patients were analyzed to clarify the clinical features of NMO patients with IgG2 AQP4 antibody.MethodsSerum samples from 58 NMO patients, who met the revised 2006 criteria for NMO, were analyzed for AQP4 antibody subclass expression using an established flow cytometric assay, and clinical features were compared according to the main AQP4 antibody subclasses.ResultsA total of 50 patients (86.2%) had IgG1 AQP4 antibodies, while eight (13.8%) expressed IgG2 AQP4 antibody as the main subclass. Those eight individuals exhibited younger age of onset (P= 0.0089), lower AQP4 antibody titers (P= 0.0024) and a more common fulfillment of Barkhof's criteria (P= 0.0466) than patients with IgG1 AQP4 antibody expression.ConclusionsResults from the present study suggest that the characteristics of individuals with IgG2 AQP4 antibody as a main subclass are more similar to multiple sclerosis and somewhat distinct from NMO patients with IgG1 AQP4 antibody.